Loading quotes...

Forecast

The analysts' average price target is €50.68 (-2.41%). The median is €50.68 (-2.41%).

Buy	4
Hold	5
Sell	0

News Go to news feed

Morphic Medical appoints Jane Wright as CFO

Morphic Medical has appointed Jane Wright as its new chief financial officer. Wright brings more than 30 years of experience in finance and operations roles at international medical device companies, most recently as finance & operations director at Apollo Endosurgery. The appointment follows Mike Gutteridge’s naming as CEO and comes at a time when Morphic Medical has received CE and MHRA market approvals for the RESET® device and has begun sales in Germany. Crystal Amber Fund Limited holds 96.7% of the issued shares, and Wright is expected to support the long-term financial strategy and further growth. » More on de.investing.com
Morphic Medical appoints Mike Gutteridge as CEO for European expansion

Morphic Medical has appointed Mike Gutteridge as its new CEO to drive expansion in Europe. The leadership change follows the CE approval of the RESET® therapy, an innovative endoscopic treatment for obesity and type 2 diabetes. Gutteridge brings over thirty years of experience in the medical technology sector and is expected to lead the company into a new phase of growth. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Morphic Holding Inc has already paid €0.31 in dividends. The last payout was in March 2022.

Financials

In the last year, Morphic Holding Inc had revenue of €471.3k and net profit of -€137.59m

(EUR)	2023	YoY
Revenue	471.3k	99.29%
Gross profit	-515.62k	100.79%
Net profit	-137.59m	149.97%
EBITDA	-160.65m	176.21%

Fundamentals

Metric	Value
Market capitalization	€2.55bn
Number of shares	50.22m
52-week high/low	€50.68 - €17.20
Dividends	No
Beta	1.49
P/E ratio	-15.87
PEG ratio	1.41
P/B ratio	3.47
P/S ratio	5,493.87

Company profile

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Name	Morphic Holding Inc
CEO	Praveen P. Tipirneni
Headquarters	Waltham, ma Netherlands
Website	morphictx.com
Sector	Utilities
Industry	Chemicals
IPO	27/06/2019
Employees	128